The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride), for the treatment of schizophrenia, a chronic mental health disorder. Developed by Karuna Therapeutics and now owned by Bristol Myers Squibb, Cobenfy works by targeting cholinergic receptors unlike traditional antipsychotic medications that target dopamine receptors. This marks a significant departure from the conventional approach to schizophrenia treatment, according ...

Diabetes is an ailment that cannot curbed entirely but controlled. The patients of diabetes often experience spiking blood sugar levels due to insufficient insulin generated in the body. While type-1 diabetes is visible since childhood, diabetes type-2 affects the middle aged people and mostly those in their 50s or 60s. In India too, it’s the most common disease affecting millions ...

A surprising discovery shows that a widely used and 20-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs. Encountering bacteria with innocent names such as Pseudomonas aeruginosa and Enterobacteriaceae can lead to hospitalisation and – in a worst-case scenario – can also be life-threatening. The bacteria, ...